TY - JOUR
T1 - Results from the second WHO external quality assessment for the molecular detection of respiratory syncytial virus, 2019-2020
AU - WHO RSV Surveillance Group
AU - WHO RSV Surveillance Group
AU - Williams, Thomas
AU - Jackson, Sandra
AU - Barr, Ian
AU - Bi, Shabana
AU - Bhiman, Jinal
AU - Ellis, Joanna
AU - von Gottberg, Anne
AU - Lindstrom, Stephen
AU - Peret, Teresa
AU - Rughooputh, Sanjiv
AU - Viegas, Mariana
AU - Hirve, Siddhivinayak
AU - Zambon, Maria
AU - Zhang, Wenqing
AU - Dia, Ndongo
AU - Razanazatovo, Norosoa
AU - Al-Nabet, Ajaeb Dakhilalla M H
AU - Abubakar, Abdinasir
AU - Tivane, Almiro
AU - Barakat, Amal
AU - Naguib, Amel
AU - Aziz, Ammar
AU - Vicari, Andrea
AU - Moen, Ann
AU - Govindakarnavar, Arunkumar
AU - Hall, Aron
AU - Darmaa, Badarch
AU - Nathalie, Bastien
AU - Herring, Belinda
AU - Caetano, Braulia C
AU - Whittaker, Brett
AU - Baumeister, Elsa
AU - Nakouné, Emmanuel
AU - Guthrie, Erica
AU - Inbanathan, Francis
AU - Nair, Harish
AU - Campbell, Harry
AU - Kadjo, Herve A
AU - Oumzil, Hicham
AU - Heraud, Jean-Michel
AU - Mott, Joshua A
AU - Namulondo, Joyce
AU - Leite, Juliana
AU - Nahapetyan, Karen
AU - Al Ariqi, Lubna
AU - Gazo, Mahmoud Hamad Ibraheem
AU - Chadha, Mandeep
AU - Pisareva, Maria
AU - Venter, Marietjie
AU - Siqueira, Marilda M
AU - Lumandas, Mayan
AU - Niang, Mbayame
AU - Albuaini, Mona
AU - Salman, Muhammad
AU - Oberste, Steve
AU - Srikantiah, Padmini
AU - Tang, Patrick
AU - Couto, Paula
AU - Smith, Peter
AU - Coyle, Peter Valentine
AU - Dussart, Philippe
AU - Nguyen, Phuong Nam
AU - Okada, Pilailuk Akkapaiboon
AU - Wijesinghe, Pushpa Ranjan
AU - Samuel, Reuben
AU - Brown, Richard
AU - Pebody, Richard
AU - Fasce, Rodrigo
AU - Jha, Runa
AU - Lindstrom, Stephen
AU - Gerber, Sue
AU - Potdar, Varsha
AU - Dong, Xiaomin
AU - Deng, Yi Mo
N1 - Funding Information:
The authors are grateful to the National Influenza Centres, Public Health Laboratories, and the Ministries of Health of the participating countries for participating in Phase II of the WHO Global RSV Surveillance EQA 2019–2020. We thank the Respiratory Viruses Branch, Division of Viral Diseases, CDC, Atlanta; the Public Health England at Colindale; the National Institute of Communicable Diseases, Johannesburg and The Peter Doherty Institute for Infection and Immunity, WHO Collaborating Centre for Reference and Research on Influenza, VIDRL, Australia, and the International Reagent Resources (IRR), Centers for Disease Control and Prevention, Atlanta, GA, USA, for providing support for the implementation of Phase II. We would like to thank Tiina Talts for performing whole genome sequencing of the PHE/UKHSA RSV genomes included in this analysis; and Boitshoko Mahlangu, Thabo Mohale, Daniel Amoako and Josie Everatt for processing and analysing the NICD RSV genomes.
Funding Information:
The WHO global RSV surveillance project was supported by an award made to the World Health Organization by the Bill and Melinda Gates Foundation (grant no. OPP1127419). Funding information
Publisher Copyright:
© 2023 The Authors. Influenza and Other Respiratory Viruses published by John Wiley & Sons Ltd.
PY - 2023/1/18
Y1 - 2023/1/18
N2 - BACKGROUND: External quality assessments (EQAs) for the molecular detection of human respiratory syncytial virus (RSV) are necessary to ensure the standardisation of reliable results. The Phase II, 2019-2020 World Health Organization (WHO) RSV EQA included 28 laboratories in 26 countries. The EQA panel evaluated performance in the molecular detection and subtyping of RSV-A and RSV-B. This manuscript describes the preparation, distribution, and analysis of the 2019-2020 WHO RSV EQA.METHODS: Panel isolates underwent whole genome sequencing and in silico primer matching. The final panel included nine contemporary, one historical virus and two negative controls. The EQA panel was manufactured and distributed by the UK National External Quality Assessment Service (UK NEQAS). National laboratories used WHO reference assays developed by the United States Centers for Disease Control and Prevention, an RSV subtyping assay developed by the Victorian Infectious Diseases Reference Laboratory (Australia), or other in-house or commercial assays already in use at their laboratories.RESULTS: An in silico analysis of isolates showed a good match to assay primer/probes. The panel was distributed to 28 laboratories. Isolates were correctly identified in 98% of samples for detection and 99.6% for subtyping.CONCLUSIONS: The WHO RSV EQA 2019-2020 showed that laboratories performed at high standards. Updating the composition of RSV molecular EQAs with contemporary strains to ensure representation of circulating strains, and ensuring primer matching with EQA panel viruses, is advantageous in assessing diagnostic competencies of laboratories. Ongoing EQAs are recommended because of continued evolution of mismatches between current circulating strains and existing primer sets.
AB - BACKGROUND: External quality assessments (EQAs) for the molecular detection of human respiratory syncytial virus (RSV) are necessary to ensure the standardisation of reliable results. The Phase II, 2019-2020 World Health Organization (WHO) RSV EQA included 28 laboratories in 26 countries. The EQA panel evaluated performance in the molecular detection and subtyping of RSV-A and RSV-B. This manuscript describes the preparation, distribution, and analysis of the 2019-2020 WHO RSV EQA.METHODS: Panel isolates underwent whole genome sequencing and in silico primer matching. The final panel included nine contemporary, one historical virus and two negative controls. The EQA panel was manufactured and distributed by the UK National External Quality Assessment Service (UK NEQAS). National laboratories used WHO reference assays developed by the United States Centers for Disease Control and Prevention, an RSV subtyping assay developed by the Victorian Infectious Diseases Reference Laboratory (Australia), or other in-house or commercial assays already in use at their laboratories.RESULTS: An in silico analysis of isolates showed a good match to assay primer/probes. The panel was distributed to 28 laboratories. Isolates were correctly identified in 98% of samples for detection and 99.6% for subtyping.CONCLUSIONS: The WHO RSV EQA 2019-2020 showed that laboratories performed at high standards. Updating the composition of RSV molecular EQAs with contemporary strains to ensure representation of circulating strains, and ensuring primer matching with EQA panel viruses, is advantageous in assessing diagnostic competencies of laboratories. Ongoing EQAs are recommended because of continued evolution of mismatches between current circulating strains and existing primer sets.
KW - laboratory diagnostics and systems
KW - respiratory diseases
KW - strengthening laboratory capacity for infectious disease control
U2 - 10.1111/irv.13073
DO - 10.1111/irv.13073
M3 - Article
C2 - 36824313
SN - 1750-2640
VL - 17
SP - e13073
JO - Influenza and other respiratory viruses
JF - Influenza and other respiratory viruses
IS - 1
M1 - e13073
ER -